# Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-to-participate-in-jefferies-global-healthcare-confere-9abd2552
Ticker: BDTX
Company: Black Diamond Therapeutics
Source: Black Diamond Therapeutics
Published: 2026-05-22 12:00 EST
Original Source URL: https://investors.blackdiamondtherapeutics.com/news-releases/news-release-details/black-diamond-therapeutics-participate-jefferies-global-1
## Summary

CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca,

## Article Body
CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, in New York, NY. In addition, the company will host one-on-one meetings with investors on the same day.

Presentation details are as follows:

4:55-5:25pm ET on Wednesday, June 3

The Webcast will be available at the start of the presentation under “Events and Presentations” on the Investors section of the Company’s website, www.blackdiamondtherapeutics.com . A replay of the webcast will also be available and archived for 90 days following the event.

About Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing silevertinib, an investigational brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR-mutant NSCLC and GBM. For more information, please visit www.blackdiamondtherapeutics.com .

Contacts

For Investors: investors@bdtx.com

For Media: media@bdtx.com
## Recent Company News
- 2026-05-22 12:00 EST — [Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-to-participate-in-jefferies-global-healthcare-confere-9abd2552) — Source: Black Diamond Therapeutics
- 2026-05-21 21:14 EST — [Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-announces-positive-phase-2-results-for-silevertinib-in-frontline-nsclc-patients-with-egfr-non-classical-mutations) — Source: Black Diamond Therapeutics
- 2026-05-19 12:00 EST — [Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-to-host-webcast-for-investors-highlighting-updated-results-from-phase-2-trial-of-silevertinib-in-1l-egfrm-nsclc) — Source: Black Diamond Therapeutics
- 2026-05-07 11:30 EST — [Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Black Diamond Therapeutics
- 2026-04-21 14:40 EST — [Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-announces-oral-presentation-of-silevertinib-phase-2-data-in-frontline-egfrm-nsclc-patients-at-the-2026-asco-annual-meeting) — Source: Black Diamond Therapeutics
## Related News
- 2026-07-22 21:05 EST — SUPN — [Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026](https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-announce-second-quarter-2026-financial-results-and-h-58b4f63d)
- 2026-07-22 20:15 EST — MOH — [Molina Healthcare Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/MOH/molina-healthcare-reports-second-quarter-2026-financial-results-343e2d32)
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)